SCHEDULE: T. Rowe Price Discloses 4.8% Stake in Praxis Precision
Beneficial Ownership Disclosure
T. Rowe Price Associates, Inc. has filed an amended Schedule 13G, reporting a 4.8% beneficial ownership stake in Praxis Precision Medicines I as of September 30, 2025.
Summary
- T. Rowe Price Associates, Inc. reported beneficial ownership of 1,003,545 shares of common stock in Praxis Precision Medicines I.
- This ownership represents 4.8% of the total class of securities.
- The filing is an Amendment No. 1 to a Schedule 13G, indicating a change or update to a previously reported stake.
- T. Rowe Price Associates, Inc. holds sole voting power over 987,882 shares and sole dispositive power over 1,003,490 shares.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: Neutral, as this is a routine disclosure of passive institutional ownership and does not contain specific positive or negative news about the issuer's operations or financial performance.
Future Outlook
NA
Industry Context
This filing is a routine disclosure by a major institutional investor, T. Rowe Price Associates, Inc., regarding its passive ownership stake in Praxis Precision Medicines I. Such Schedule 13G filings are common for investment managers holding less than 5% of a company's shares, indicating a standard investment position rather than an activist intent or a significant strategic shift.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's passive stake, which can offer some level of confidence in the company's investment profile.
Key Dates
| Date | Description |
|---|---|
| 09/30/2025 | Date of the event which required the filing of this statement, reflecting the reported beneficial ownership percentage. |
| 11/14/2025 | Date the Schedule 13G Amendment No. 1 was signed and filed with the SEC. |
Keywords
Praxis Precision Medicines, T. Rowe Price, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.